EPI Health is continually expanding our prescription product line to offer healthcare professionals and patients new and better options to treat skin conditions.
MINOLIRA is a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
For more information, visit www.minolira.com
Cloderm® Cream 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Cloderm® Cream 0.1% contains the medium potency topical corticosteroid, clocortolone pivalate, in a specially formulated water washable emollient cream base.
For more information, visit www.clodermcream.com.
Bensal HP® is indicated for the external treatment of inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Bensal HP® is also indicated in the treatment of insect bites, burns and fungal infections.
For more information, visit bensalhp.com.
Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.
IMPORTANT SAFETY INFORMATION Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product. Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients. Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal. In a controlled clinical trial Sitavig’s most common side effects (greater than or equal to 1%) were: headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Click here for Full Prescribing Information.
Bionect® is indicated for the dressing and management of partial to full thickness dermal ulcers (pressure sores, venous stasis ulcers, arterial ulcers, diabetic ulcers); wounds including cuts, abrasions, donor sites and post-operative incisions; irritations of the skin; and first- and second-degree burns. The dressing is intended to cover a wound or burn on a patient’s skin, and protect against abrasion, friction and desiccation.
For more information, visit bionect.com.